Pneumatosis Cystoides Intestinalis: What’s the Truth?

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

ZORYVE® (roflumilast) cream 0.15% is a once-daily, steroid-free PDE4 inhibitor approved for the treatment of mild to moderate atopic dermatitis in patients aged 6 and older. Clinical trials demonstrate its rapid onset, strong efficacy, and favorable safety profile, with emerging evidence supporting its use in younger children and as a long-term maintenance therapy to prevent flares.

EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.